Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy

Project description

A strategy to prevent tumour progression

The cancer research and medical oncology communities are deliberating between nutrient deprivation and supplementation approaches to prevent tumour progression. Studies have indicated that cyclic fasting or fasting-mimicking diets that restrict nutrients reduce tumour progression. The ERC-funded METABALANCANCER project aims to develop a new strategy for halting tumour progression and improving treatment response. It will explore combinations of targeted metabolite supplementation and global nutrient restriction, using various techniques, such as biochemical experiments, isotope tracing experiments and integrated omics analyses, to identify the cell-autonomous and immune-mediated mechanisms that underlie the anti-tumour effects of targeted metabolite supplementation in combination with global nutrient restriction. METABALANCANCER will test the most effective metabolite supplementation restriction strategy in advanced triple-negative breast cancer patients.

Objective

The goal of this proposal is to explore combinations of targeted metabolite supplementation and global nutrient restriction as a new strategy to reprogram tumor metabolism, to halt tumor progression and to improve response to treatments.
Preclinical and clinical studies published by our group and by others showed that global nutrient restriction, in the form of cyclic fasting or fasting-mimicking diets (FMDs), produces desirable metabolic and immunologic effects that result in reduced tumor progression and in the prolongation of animal/patient survival. Of note, our unpublished results indicate that the supplementation of specific amino acids or fatty acids has in vitro and in vivo antitumor effects, which are strongly enhanced when metabolite supplementation is combined with nutrient starvation.
By employing canonical cell biology and biochemical experiments, polysome/ribosome profiling, isotope tracing experiments and integrated omics (transcriptomic, proteomic, metabolomic) analyses in in vitro and in vivo murine and human tumor models, here we propose to:
- identify the cell-autonomous and immune-mediated mechanisms at the basis of the antitumor effects of targeted metabolite supplementation in combination with global nutrient restriction;
- identify the most effective metabolite supplementation-restriction strategy to be tested in a first-in-human clinical trial in patients with advanced triple-negative breast cancer.
While the basic cancer research and medical oncology communities are engaged in a historical scientific and clinical diatribe on the use of nutrient deprivation vs. supplementation approaches to halt tumor progression and to improve patient survival, we will exploit our unprecedented ability to conduct parallel preclinical and clinical experimentation in the field of cancer metabolism to identify new and effective combinations of balanced metabolite supplementation and restriction, with relevant scientific and translational implications.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-STG

See all projects funded under this call

Host institution

UNIVERSITA DEGLI STUDI DI MILANO
Net EU contribution
€ 755 120,00
Address
Via Festa Del Perdono 7
20122 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 755 120,00

Beneficiaries (3)